Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663340 | 1.00 | TRPM8 (0.69) | TRPM8ALDH1A1HPGDMALT1SMN1; SMN2 | |
| SCHEMBL6334721 | 0.90 | TRPM8 (0.73) | TRPM8ALDH1A1SMN1; SMN2NPSR1L3MBTL1 | |
| SCHEMBL19189293 | 0.88 | TRPM8 (0.70) | TRPM8ALDH1A1HPGDMALT1SMN1; SMN2 | |
| SCHEMBL371165 | 0.88 | TRPM8 (0.70) | TRPM8ALDH1A1HPGDSMN1; SMN2LMNA | |
| SCHEMBL2628764 | 0.88 | TRPM8 (0.65) | TRPM8ALDH1A1 | |
| SCHEMBL10072945 | 0.87 | TRPM8 (0.69) | TRPM8MAPT | |
| SCHEMBL2628755 | 0.85 | TRPM8 (0.63) | TRPM8ALDH1A1MALT1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12835229 | 0.85 | ALDH1A1 (0.56) | TRPM8ALDH1A1HPGDMALT1SMN1; SMN2 | |
| SCHEMBL15131638 | 0.85 | TRPM8 (0.63) | TRPM8ALDH1A1MALT1SMN1; SMN2L3MBTL1 | |
| SCHEMBL4883161 | 0.84 | TRPM8 (0.67) | TRPM8ALDH1A1HPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1656144-B2 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-8389730-B2 | Compositions and methods for the treatment of disease associated with TRP-P8 expression | DENDREON CORPORATION (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | DENDREON CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | GENENTECH, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893072-B2 | Cool-genic compounds as anticarcinogenic agents promoting apoptosis and inhibit angiogenesis; antiproliferative agents | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094977-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH TRP-P8 EXPRESSION | TRPC4, TRPC3, TRPC1 | TRPM8 8/4885ALDH1A1 4742/4885HPGD 1277/4885 |
| US-20120045448-A1 | TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS | TSG101, TP53, BAX | TRPM8 28/4885ALDH1A1 3429/4885HPGD 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.